InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.046 0.002 (4.55%)+
Announcement
Release
20 Aug 2026 9:11AM
Price at Release
$0.044
Full Release
download
Summary
Emyria Limited, an innovative leader in mental health treatments, announced the resolution of Authorised Prescriber capacity constraints across its Perth and Queensland operations, which had previously hindered clinical activity expansion. This bottleneck removal, coupled with the recruitment of 15 new therapists, aims to increase treatment capacity, targeting additional dosing days in Q4 2026. The new recruits, primarily Clinical Psychologists, Mental Health Occupational Therapists, and Mental Health Nurses, will undergo training and onboarding to maximize the utilization of existing prescribing and clinical infrastructure. This strategic workforce expansion aligns with the global momentum in psychedelic medicine, supported by significant investment and clinical validation, offering a capital-efficient path to increased treatment volumes and revenue growth.
Key Points
  • Resolution of Authorised Prescriber capacity constraints.
  • Recruitment of 15 new therapists.
  • Targeted Q4 2026 dosing expansion in Perth.
  • 87% of recruits meet revised TGA Lead Therapist eligibility.
  • Increased utilisation of existing clinical infrastructure.
  • Global investment in psychedelic medicine supports Emyria's strategy.
  • Capital-efficient pathway to higher treatment volumes and revenue growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.